CD274 and breast carcinoma: Recently, due to exciting effect of immunotherapy targeting to immune checkpoint, T-cell inhibitory molecule programed death-ligand 1 (PD-L1), overexpressed in malignant cells including breast cancer cells, could escape from immunological surveillance [12].